You are here

Samsung Bioepis races to get biosimilar drugs on the market

Korean conglomerate hopes its biopharmaceuticals push can help offset a slowing smartphone market

Bioepis employees at its laboratory in Incheon. To quickly get up to speed in an unfamiliar industry, Samsung enlisted drugmaker Biogen as a Bioepis shareholder, scouted industry veterans from firms such as Novartis and Eli Lilly and surrounded them with young recruits.


AS Samsung Bioepis raced to be first to market with a copy of Enbrel, a blockbuster rheumatoid arthritis drug, countdown clocks reminded workers: heading for lunch, meetings or even the washroom: of the days to the first mass production run.

Founded four years ago by South...

Market voices on: